The basic biochemical mechanisms underlying many heritable human polycystic diseases are unknown despite evidence that most cases are caused by mutations in members of several protein families, the most prominent being the polycystin gene family, whose products are found on the primary cilia, or due to mutations in posttranslational processing and transport. Inherited polycystic kidney disease, the most prevalent polycystic disease, currently affects Ϸ500,000 people in the United States. Decreases in proteoglycans (PGs) have been found in tissues and cultured cells from patients who suffer from autosomal dominant polycystic kidney disease, and this PG decrease has been hypothesized to be responsible for cystogenesis. This is possible because alterations in PG concentrations would be predicted to disrupt many homeostatic mechanisms of growth, development, and metabolism. To test this hypothesis, we have generated mice lacking xylosyltransferase 2 (XylT2), an enzyme involved in PG biosynthesis. Here we show that inactivation of XylT2 results in a substantial reduction in PGs and a phenotype characteristic of many aspects of polycystic liver and kidney disease, including biliary epithelial cysts, renal tubule dilation, organ fibrosis, and basement membrane abnormalities. Our findings demonstrate that alterations in PG concentrations can occur due to loss of XylT2, and that reduced PGs can induce cyst development.
D
evelopment of cysts, most frequently in the kidneys and/or liver, is a hallmark of hereditary polycystic disease. Patients experience high morbidity from cyst rupture, infection, and/or destruction of normal tissue. The most common polycystic disease (at 1 in 500 births) and the most studied is autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in either PKD1 or PKD2 (1) (2) (3) (4) (5) (6) (7) (8) . ADPKD patients develop decreased renal function, renal tubule dilation, and cysts, and 70% develop liver biliary cysts. Alterations in epithelial cell growth and development, fluid secretion, polarization, and/or apoptosis (7) (8) (9) (10) (11) have all been linked to cyst development and growth and are thought to arise from abnormalities in the extracellular matrix (ECM), basement membrane (BM), and cellular mechanosensing and signaling by the primary cilium (7) (8) (9) (10) (12) (13) (14) (15) (16) (17) (18) (19) (20) .
Proteoglycans (PGs) are located on the cell surface and in the ECM and consist of a core protein with heparan sulfate (HS), chondroitin sulfate (CS), and dermatan sulfate glycosaminoglycan (GAG) side chains assembled on select serines. They influence many fundamental biological processes, including cytokine and growth factor function, morphogen gradient formation, and BM homeostasis (21) (22) (23) (24) . Therefore, the reduction in PGs observed in tissues and cultured cells from ADPKD patients and polycystic kidney disease (PKD) animal models (9, 10, 16, 18) correlates well with the cyst-associated epithelial abnormalities of dedifferentiation, proliferation, and increased cell turnover. Despite this strong link to ADPKD, the role of PGs in ADPKD and other polycystic diseases has not been systematically studied. We have investigated the role that PGs play in the development of human polycystic disease by inactivating xylosyltransferase 2 [(XylT2) Enzyme Commission no. 2.4.2.26], an enzyme shown to be involved in HS and CS biosynthesis (25) (26) (27) . We have shown in an experimental model system that reduced PGs are cystogenic.
Results

Mice Lacking XylT2
Have Significantly Reduced Liver PGs. The XylT family consists of XYLT1 and XYLT2. In mice, Xylt2 mRNA is detected as a single transcript in a wide range of tissues, including the kidney, and it is the only XylT detected in the liver (Fig. 1a) . This tissue distribution is similar to that in humans (28) and is consistent with XylT2 having an important function in liver and kidney homeostasis. Using gene targeting in embryonic stem cells, we deleted 94% of the coding sequence of the Xylt2 locus [supporting information (SI) Fig. 6 ]. Heterozygous (Xylt2 Ϫ/ϩ ) matings yielded the expected Mendelian ratios of mice (data not shown). Livers from Xylt2 Ϫ/Ϫ mice did not express either Xylt2 mRNA (SI Fig. 7a ) or Xylt1 mRNA (data not shown) as measured by real-time RT-PCR analyses with total RNA. Therefore, based on the lack of Xylt mRNA and the loss of coding sequence, the Xylt2 Ϫ/Ϫ livers were considered devoid of known XylTs. As expected, the kidneys expressed no detectable Xylt2 mRNA (SI Fig. 7b ). Unexpectedly, a slight decrease in Xylt1 mRNA levels relative to controls was found (SI Fig. 7c ), but was not significant. Mutant liver PG levels were substantially decreased, with HS levels 87% reduced compared with controls ( Fig. 1b and SI Fig. 7d ). In the mutant livers, we found that HS was absent in the sinusoids, whereas residual HS, most likely Author contributions: F.L., R.D.C., and M.E.H. designed research; E.C. and R.S.-M. performed research; R.T. and F.L. contributed new reagents/analytic tools; S.K., T.S., R.T., F.L., and M.E.H. analyzed data; and M.E.H. wrote the paper.
from Xylt1 expression, was present in the liver vasculature and in the portal triad regions (Fig. 1c) . Significantly, although Northern blot analysis and real-time RT-PCR of total RNA showed the liver to have absent Xylt1, residual Xylt1 mRNA was demonstrated with real-time RT-PCR by using poly(A) RNA as a template (SI Fig. 8) . Predictably, the core proteins in the sinusoids should lack GAG side chains, and indeed Western blots on extracted proteins using an antibody against decorin showed that the mutants expressed decorin at levels similar to controls, but mostly lacked GAG side chains (Fig. 1d) . Therefore, the Xylt2 Ϫ/Ϫ mice have a deficit of PGs in the liver due to a loss of GAG side chains.
Xylt2 ؊/؊ Mice Develop Liver Cysts. Despite relatively normal hepatic development, numerous cysts were found beginning at 4 to 5 months of age in 50% of the Xylt2 Ϫ/Ϫ livers in males and females. No cysts were found in sibling controls (Fig. 2 a and b) . Most cysts by gross examination appeared to emerge from within the liver and not the extrahepatic biliary tract. The portal triad areas in noncystic portions of mutant liver contained increased cell numbers relative to controls arising from biliary epithelial cell (BEC) hyperplasia and small basophilic mononuclear cells speculated to be inflammatory or oval cells (Fig. 2 a and b) . Oval cell proliferation often accompanies BEC hyperplasia after liver injury (29) . However, these cells were found to be CD45-positive inflammatory cells (Fig. 2 c and d) . Furthermore, the liver portal triad areas showed increased fibrosis that diminished in the sinusoidal areas surrounding the portal triad (Fig. 2e) . Mutant liver weights were significantly greater than controls even when the livers were cyst-free at 3 to 5 months of age and in 10-month-old animals with no liver cysts or in livers drained of cystic fluid (Fig. 2g) . The liver cysts were susceptible to rupture, as shown by sequential MRI scans (Fig. 2f ) . The cystic fluid was generally clear and acellular, but was occasionally brown and rarely green tinged, suggesting the presence of blood or bile, respectively. The walls of the cysts were lined with cuboidalcolumnar cytokeratin-19-positive BECs (Fig. 2h) . Below the BECs was a layer of fibrous connective tissue containing collagen ( Fig. 2h and SI Fig. 9 ) and hyperplastic biliary tracts containing and surrounded by small basophilic mononuclear cells, similar to those in the triad areas. Despite these abnormalities, liver enzymes were normal (see Materials and Methods, data not shown). Therefore, XylT2 deficiency results in significant liver abnormalities, including biliary tract hyperplasia, liver fibrosis, and biliary cysts that initiate and progress with age. However, despite these abnormalities, liver development and function are normal. These features closely resemble many of those observed in livers of ADPKD patients (9, 30, 31) .
Xylt2 ؊/؊ Mice Develop Renal Defects. The hallmark renal lesion in human ADPKD is dilation of renal tubules progressing to cyst development (8) . The 9-to 10-month-old male Xylt2 Ϫ/Ϫ mice had varying numbers of dilated tubules localizing primarily to the kidney cortex (0/8 Xylt2 ϩ/ϩ , 4/7 Xylt2 Ϫ/Ϫ ; P ϭ 0.03). Some had extensive tubular involvement, but the majority had at most one to two dilated tubules lined with cuboidal epithelium, suggesting that dilation was not due to increased pressure (Fig. 3a) . Because there was no evidence that the dilated segments had separated from the nephron, these structures were not considered cysts. Interstitial fibrosis was observed throughout the mutant kidneys (Fig. 3b) . These findings are similar to the range of incidence and severity of renal abnormalities in Pkd1 Ϫ/ϩ and Pkd2 Ϫ/ϩ knockout mice (32) . Furthermore, at 3 and 10 months of age, kidneys of the Xylt2 Ϫ/Ϫ mice weighed significantly more than those of controls (Fig. 3c) . We observed a significant increase in hydronephrosis grossly (SI Fig. 10 ) and histologically in 6-to 7-monthold mutants (six of eight animals; P ϭ 0.007) and in 9-to 10-month-old mutants (five of seven animals; P ϭ 0.04) compared with zero affected age-matched controls. MRI analysis showed a similar increase in hydronephrosis at 11 to 12 months of age (0/7 Xylt2 ϩ/ϩ , 7/8 Xylt2 Ϫ/Ϫ ; P ϭ 0.001) (Fig. 3d) . No other urinary tract abnormalities were observed, suggesting that the hydronephrosis was not due to physical urinary outflow obstruction. We hypothesize that the hydronephrosis may develop because the structural integrity of the renal pelvis might be affected by global XylT2 deficiency. The Xylt2 Ϫ/Ϫ mice exhibited reduced renal function shown as a significant increase in blood urea nitrogen (BUN) in younger (21% increase) and older (36% increase) animals (Fig. 3e ). Because this increase in BUN levels is seen in the younger animals in the absence of hydronephrosis, a primary kidney defect unrelated to the hydronephrosis is likely. Similar to the liver, the mutant kidneys contained substantial GAG-free core protein (Fig. 3f ) , in contrast to normal total GAG levels as measured by alcian blue precipitation (SI Fig. 11 ). This finding suggests that renal decorin is more dependent on XylT2 activity than other core proteins. Normal renal versican modification levels ( Fig. 3g ) and similar levels of renal CS and HS in mutants and controls support this conclusion (SI Figs. 12 and 13). We speculate that the lack of overt tubule cysts suggests compensatory XylT1 activity in the kidney.
Xylt2 ؊/؊ Mice Cystic BMs Resemble Those in PKD. In ADPKD patients, renal epithelial tubule BM thickening and lamination with loss of protein homogeneity are postulated to cause cyst development and progression (9, 12, 14, 17, 33) . In the cystic BM of the Xylt2 Ϫ/Ϫ mice, we observed several consistent ultrastructural abnormalities (Fig. 4) . The basolateral junctions of mutant BECs have membranous lateral projections that interdigitate with those of adjacent cells (Fig. 4 b and e) . These lateral projections appear similar to those described in early characterizations of the PKD mouse model Cys-1 cpk (34) . The mutant BEC BM, in contrast to the uniform and easily visible control BM, has sections that are diffuse, indistinct, and thickened (Fig. 4 b and  c) . The apical portions of the mutant BECs contain tight junctions similar to the controls, but some of the cells have secretory-appearing vesicles not seen in control BECs (Fig. 4 c,  d , and f ). Because epithelial secretion is an important component of cyst development and progression (9) , this finding is significant. We conclude that XylT2 deficiency causes ultrastructural changes in the cyst-associated BECs and their BM similar to those seen in PKD animal models and ADPKD.
Cystic Epithelium in Xylt2 ؊/؊ Mice Has Increased ␤-Catenin. Transgenic mice overexpressing ␤-catenin develop cysts (35) , and abnormalities in cellular signaling involving ␤-catenin are likely mechanistically involved in cyst development (7) . Similarly, we observed increased ␤-catenin in the cystic epithelial cells in the mutant (Fig. 5) . Therefore, cystic BECs' ␤-catenin expression in Xylt2 Ϫ/Ϫ mice is likely important mechanistically in cyst development.
Discussion
In this paper, we find that Xylt2 inactivation causes severe reduction in liver PG content. Despite this reduction, the Xylt2 Ϫ/Ϫ mice develop normally. However, the mice develop liver biliary epithelial cysts, renal tubule dilation/cysts, and decreased renal function. These changes are very similar to those of PKD patients. We have shown previously that XylT2, the product of the Xylt2 locus, is important in PG biosynthesis in many cell types (25) , and in this paper we show that Xylt2 mRNA is widely expressed as a single transcript. In addition to BEC hyperplasia and cyst development, Xylt2 deficiency results in ultrastructural changes in the BEC BM and basolateral and apical portions of the cell, all of which are supportive of a role of XylT2-dependent PGs in the development of cysts.
The mechanism of the decreased PG in PKD is unknown. It could be rooted in increased degradation and/or reduced biosynthesis. Recent renal expression profiling from human ADPKD kidneys shows that matrix metalloprotease 1 expression increases and the PG biosynthetic enzyme ␤1,3-glucuronyltransferase 3 decreases in ADPKD (36) . In addition, increased metalloprotease activity has been measured in PKD patient and animal model tissues (8, 18, 37) . Because XylT2 and XylT1 catalyze the initial and proposed rate-limiting step of PG biosynthesis, a role of XylT activity in the pathogenesis of PKD is plausible. Could there be a subpopulation of PKD patients that may have a mutant XYLT responsible for cyst development? It is unlikely because most cases of PKD are a result of a PKD1, PKD2, or PKHD1 mutation. Nonetheless, linkage analysis of XYLT polymorphisms with PKD patients has not been reported. More likely there is a larger PKD patient subgroup with known PKD1, PKD2, or PKHD1 mutations with linked XYLT polymorphisms associated with decreased enzyme activity resulting in a particular clinical picture (e.g., liver cysts in addition to renal cysts). In these cases, the mutated XYLT allele and product would be a genetic modifier of the PKD phenotype. Alternatively, alterations in the activity of other downstream enzymes of PG biosynthesis (e.g., ␤1,3-glucuronyltransferase 3) by defective polycystin-1 signaling could reduce PG biosynthesis, leading to cyst development.
Many PKD animal models have expedited the search for pathologic mechanisms of cyst development as well as for treatments (7, 38) . The Xylt2 Ϫ/Ϫ mice are a unique PKD animal model. PKD animal models have been indispensable in correlating dysfunctional primary cilia proteins with PKD (7, 20, 38) . Other models show that proteins involved in biological processes ranging from cell cycle to gene transcription can be cystogenic (7, 38) . Hypomorphic mutated laminin ␣-5 is the only ECM-associated protein mutation known to cause PKD (19) . The Xylt2 Ϫ/Ϫ mice show that decreased PGs can cause cyst development.
As with other PKD models, the Xylt2 Ϫ/Ϫ mice reveal important aspects of basic biology. Several intriguing biological facts about the role of PGs in organ development and homeostasis are observed. First, the fact that liver development occurs in these mice is significant because liver PGs are influential in hepatocellular differentiation (39) (40) (41) . XylT2 deficiency drastically reduces hepatocyte PG biosynthesis and has less effect on the vasculature and portal triad PG levels. Our results suggest that these residual PGs are sufficient for hepatocellular differentiation or that hepatocytes in vivo need minimal levels of PGs for development and maturation. Furthermore, given the widespread mRNA expression of Xylt2, that organogenesis and subsequent embryonic development can occur in the absence of XylT2 function is interesting. Second, despite such a reduction in PGs in the livers of the Xylt2 Ϫ/Ϫ mice, the liver functions relatively normally. Third, although the kidney has expression of both Xylt2 and Xylt1, it has functional as well as structural changes presumably due to the lack of XylT1 to compensate partially or fully for the absence of XylT2 function. This lack of compensation could be due to differences in substrate kinetics as well as cell type-specific expression of Xylt1. We do know that many cell types express both enzymes (25) and can plausibly up-regulate XylT1 activity to compensate for the loss of XylT2 function if the enzymes can share substrates. The preferential lack of modification of decorin illustrates that some core proteins may be more severely affected than others. These core proteins are potential mechanistic candidates linking reduced PG to cyst develop.
Whether PG homeostasis can be causally linked to ADPKD cyst development has been the subject of debate (16) . Our findings indicate that decreased PG concentrations are cystogenic. Our data suggest that ␤-catenin is involved, and we hypothesize that lack of ECM-sequestered growth factors may induce ␤-catenin activity and proliferation of BECs. With regard to polycystin dysfunction, we speculate that lack of downstream cilia-signaling events may influence ECM composition by decreasing PG biosynthesis and/or increasing degradation, leading to cystogenic changes in epithelial cells. Alternatively, polycystin-1 (PC-1) may require cilia-associated or ECM PGs for optimal function because PC-1 has multiple extracellular domains suspected to interact with the ECM and other cell surface-associated proteins (8) . In support of this hypothesis is the fact that GAG side chains are important in many proteinprotein interactions (22, 42) . These possibilities will be addressed in future studies.
Materials and Methods
Generation of Xylt2 ؊/؊ Mice. A bacterial artificial chromosome fragment encompassing most of the Xylt2 locus (Research Genetics, Huntsville, AL) was used to make the targeting Northern Blot, RT-PCR. Multitissue expression measurements by Northern blot analyses were performed by using a multitissue poly(A) Northern blot (MessageMap blot; Stratagene, La Jolla, CA). cDNA probe templates were 1.5 kb for Xylt2 and 0.5 kb for Xylt1, both encoding the final coding sequence of the cDNA sequence, including the stop codon at the 3Ј end. First-strand biosynthesis with RT was performed by using 2.5 g of total or 0.5 g of poly(A) RNA using oligo(dT) primer (Invitrogen, Carlsbad, CA). Real-time PCR was performed with standard techniques (SYBR Green PCR; Applied Biosystems, Foster City, CA) by using an ABI Prism 7000 Sequence Detection System PCR machine. See SI Materials and Methods.
Slide Preparation, Staining, Immunohistochemistry, and EM. For EM, fresh tissue was taken from animals, cut into 1-mm 3 tissue pieces fixed in 2% glutaraldehyde, and postfixed in 1% osmium tetroxide in 0.1 M caccodilate buffer. All tissues were treated with tannic acid in 0.1 M caccodilate buffer, followed by dehydration and f lat embedding in Epon (EMBed-812; Electron Microscopy Sciences, Hatfield, PA). Areas of interest were identified by light microscopy analyses of semithin sections. Ultrathin sections were collected on copper-palladium grids and double stained with uranyl acetate and lead citrate, followed by EM analysis. For liver immunohistochemistry with F69 -3G10 anti-HS antibody (Seikagaku America, Rockville, MD) for heparitinase-digested HS, the paraformaldehydefixed tissues were embedded in OCT compound (Raymond Lamb, Durham, NC) and sectioned. Sections were digested with heparitinase I (Seikagaku America) or incubated in buffer alone for 3 h at 37°C, followed by incubation with primary antibody (1:50) and reacted by using the M.O.M. peroxidase kit (PK-2200) and NovaRED (Vector Laboratories, Burlingame, CA) according to the manufacturer's instructions. Sections were counterstained with hematoxylin QS (Vector Laboratories). Oval cell immunohistochemistry was done by using the A6 antibody (43) generously provided by Valentina Factor (National Cancer Institute/National Institutes of Health, Bethesda, MD). This antibody recognizes both BEC and oval cells. It was used at a 1:10 dilution, followed by a secondary donkey anti-rat IgG Cy3 antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) on frozen sections. CD45 antibody (BD Biosciences PharMingen, San Diego, CA), CK19 antibody (ab15463; Abcam, Cambridge, MA), sirius red stain, ␤-catenin antibody (BD Biosciences Transduction Laboratories, Lexington, KY), anti-HS F58 -10E4 antibody, and anti-CS 2B6 antibody analyses were performed on paraffin-embedded sections, followed by counterstaining with hematoxylin QS (Vector Laboratories). See SI Materials and Methods.
PG Extraction and Western Blot Analyses. PGs were isolated from tissues by extraction with 7M Urea, 0.1 M NaCl, 50 mM Tris⅐HCl (pH 7.5), protease inhibitors (cat: 11-836-153-001; Roche Diagnostics, Indianapolis, IN), and 0.5% Triton X-100. Sample protein concentration was determined by using the Bradford assay (Pierce Chemical, Rockford, IL). General sample processing included dilution of 1:10, followed by digestion overnight with 0.29 units per ml of chondroitinase ABC (Seikagaku America) in Hepes 50 mM (pH 7.0), 0.1 M NaCl, 1 mM CaCl 2 , and 15 mM benzamidine at 37°C. Fifteen to forty micrograms of protein was denatured, reduced, and separated by polyacrylamide gel electrophoresis, followed by transfer to PVDF membrane (Westran 0.45 m; Schleicher & Schuell, Keene, NH Analyses. To estimate total GAGs, PGs were precipitated with alcian blue from tissue protein extracts obtained as described above (sGAG assay; Kamiya Biomedical, Thousand Oaks, CA). Pointto-point curve fitting of the standard curve was performed by using the Softmax software (Molecular Devices, Sunnyvale, CA). To ensure accuracy of the low mutant PG values, precipitated PGs from three aliquots of a mutant sample were pooled and measured. All values were normalized to total protein. For disaccharide analyses, liver pieces (Ϸ0.5 g) were frozen in liquid nitrogen, smashed, defatted with acetone, rinsed with ethyl ether, and dried. Lyophilized tissue was weighed and digested with pronase (46) . After pronase inactivation and benzonase treatment, the digested PGs were isolated by using DEAE-Sephacel chromatography. Samples were subjected to ␤-elimination (47) . After neutralization with glacial acetic acid, GAGs were precipitated with ethylic alcohol. The final pellet was dried under vacuum and resuspended in H 2 O. Disaccharide analyses were performed by using heparin lyase digestion, separation by HPLC on a Dionex ProPac PA1 anion exchange column, and UV and fluorescence detection as described (48, 49) . See SI Materials and Methods.
MRI Imaging. MRI equipment used at the OMRF Small Animal MRI Core Facility was a Bruker (Newark, DE) Biospec 7.0 Tesla/30-cm horizontal-bore imaging spectrometer. Anesthetized mice were placed in an MR probe (35-mm multirung RF volume coil), and livers were localized by MRI. Mouse livers and kidneys were imaged in vivo at ages indicated. With the available MRI equipment, cysts as small as 0.12 mm (120 m) in diameter would be detected. Respiratory gating was used to trigger acquisition of the phase-encoding steps in the imaging sequence for the images. Multiple 1H MR image slices were taken in the transverse plane using a spin-echo multislice (repetition time 1.1 sec, echo time 11.6 msec, 128 ϫ 128 matrix, five steps per acquisition, 3 ϫ 3 cm 2 field of view, 1.3 mm slice thickness).
Blood Chemistry Analyses. Serum chemistries were measured by using an Ortho Diagnostics Systems (Raritan, NJ) Vitros-250 chemistry analyzer machine. For liver function, serum aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and lactic dehydrogenase activities were obtained. See SI Materials and Methods. Statistical Analyses. For the incidence of hydronephrosis and incidence of tubule dilation, a two-tailed Fisher's exact test was performed, and other tests of significance unless stated otherwise were done by using one-way ANOVA using JMP software version 5.0.2.1 (SAS Institute, Cary, NC).
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